| 1 |
35350808 | Clinical Utility of Liquid Biopsy to Identify Genomic Heterogeneity and Secondary Cancer Diagnoses: A Case Report. | 2022 Jan-Apr |
1 |
| 2 |
32791510 | Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. | 2021 |
1 |
| 3 |
33571020 | Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. | 2021 Apr |
1 |
| 4 |
33650292 | Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. | 2021 Sep |
1 |
| 5 |
34536949 | Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. | 2021 Nov |
2 |
| 6 |
32606932 | Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer. | 2020 |
2 |
| 7 |
33193831 | Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. | 2020 |
1 |
| 8 |
29630978 | The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. | 2018 Aug |
2 |
| 9 |
30048718 | Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. | 2018 Oct 14 |
3 |
| 10 |
30131546 | Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). | 2018 Oct |
1 |
| 11 |
30344307 | Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). | 2018 Oct |
1 |
| 12 |
30509237 | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. | 2018 Dec 3 |
1 |
| 13 |
27324190 | Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. | 2017 Jan |
2 |
| 14 |
28358937 | Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. | 2017 Nov 9 |
1 |
| 15 |
26879374 | Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. | 2016 May |
4 |
| 16 |
24444537 | Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer. | 2014 Feb |
1 |
| 17 |
25131489 | [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review]. | 2014 Aug 18 |
1 |
| 18 |
23228172 | Abiraterone in metastatic prostate cancer without previous chemotherapy. | 2013 Jan 10 |
1 |
| 19 |
23532557 | Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer. | 2013 May |
3 |
| 20 |
24210085 | Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584. | 2013 Nov |
1 |
| 21 |
17825143 | [Effects of docetaxel and prednisone for hormone-refractory prostate cancer]. | 2007 Jun 26 |
1 |
| 22 |
15668260 | Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. | 2005 Mar |
1 |
| 23 |
15780173 | Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. | 2005 Feb |
2 |
| 24 |
15934892 | Which drug combination for hormone-refractory prostate cancer? | 2005 Apr |
1 |
| 25 |
15945343 | Recent progress in management of advanced prostate cancer. | 2005 Apr |
1 |
| 26 |
16217292 | Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. | 2005 Nov |
1 |
| 27 |
16266195 | Docetaxel in hormone-refractory metastatic prostate cancer. | 2005 |
1 |
| 28 |
12441935 | Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. | 2002 Dec |
2 |
| 29 |
9697790 | Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. | 1998 Aug |
4 |
| 30 |
7538247 | False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney. | 1995 May |
1 |
| 31 |
1719250 | Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. | 1991 Dec |
1 |
| 32 |
1700145 | Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. | 1990 Nov |
2 |